In this post hoc interpatient comparative effectiveness study, 1L selpercatinib demonstrated improved outcomes associated with clinical effectiveness compared to 1L standard therapies in patients with RET fusion-positive aNSCLC, RET-mutated MTC, and RET fusion-positive TC. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.